CO2024000999A2 - Inhibidores peptídicos lipídicos del receptor de interleucina-23 - Google Patents
Inhibidores peptídicos lipídicos del receptor de interleucina-23Info
- Publication number
- CO2024000999A2 CO2024000999A2 CONC2024/0000999A CO2024000999A CO2024000999A2 CO 2024000999 A2 CO2024000999 A2 CO 2024000999A2 CO 2024000999 A CO2024000999 A CO 2024000999A CO 2024000999 A2 CO2024000999 A2 CO 2024000999A2
- Authority
- CO
- Colombia
- Prior art keywords
- interleukin
- receptor
- lipid peptide
- peptide inhibitors
- inhibitors
- Prior art date
Links
- 102100036672 Interleukin-23 receptor Human genes 0.000 title abstract 4
- 101710195550 Interleukin-23 receptor Proteins 0.000 title abstract 4
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 150000002632 lipids Chemical class 0.000 title abstract 2
- 208000037979 autoimmune inflammatory disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se relaciona con nuevos inhibidores peptídicos lipídicos del receptor de interleucina-23 (IL-23R) o sales, solvatos y/u otras formas farmacéuticamente aceptables de estos, composiciones farmacéuticas, métodos y/o usos correspondientes de los inhibidores de IL-23R para el tratamiento de enfermedades inflamatorias autoinmunitarias y/o trastornos relacionados. Se incluyen varias secuencias de péptidos altamente personalizables que se adaptarán para tratar un amplio rango de dolencias.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163221697P | 2021-07-14 | 2021-07-14 | |
| PCT/US2022/037205 WO2023288019A2 (en) | 2021-07-14 | 2022-07-14 | Lipidated peptide inhibitors of interleukin-23 receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2024000999A2 true CO2024000999A2 (es) | 2024-02-05 |
Family
ID=84920513
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2024/0000999A CO2024000999A2 (es) | 2021-07-14 | 2024-01-30 | Inhibidores peptídicos lipídicos del receptor de interleucina-23 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20240173309A1 (es) |
| EP (1) | EP4370146A2 (es) |
| JP (1) | JP2024525732A (es) |
| KR (1) | KR20240034224A (es) |
| CN (1) | CN118055773A (es) |
| AU (1) | AU2022311814A1 (es) |
| CA (1) | CA3226532A1 (es) |
| CO (1) | CO2024000999A2 (es) |
| DO (1) | DOP2024000011A (es) |
| IL (1) | IL310061A (es) |
| MX (1) | MX2024000760A (es) |
| PE (1) | PE20240595A1 (es) |
| TW (1) | TW202330013A (es) |
| WO (1) | WO2023288019A2 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2968443T (pt) | 2013-03-15 | 2021-12-28 | Protagonist Therapeutics Inc | Análogos de hepcidina e seus usos |
| LT3143037T (lt) | 2014-05-16 | 2021-10-11 | Protagonist Therapeutics, Inc. | Alfa4beta7 integrino tioeterio peptidų antagonistaii |
| CN107206254B (zh) | 2014-07-17 | 2021-08-24 | 领导医疗有限公司 | 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途 |
| EP3749345A4 (en) | 2018-02-08 | 2022-04-06 | Protagonist Therapeutics, Inc. | CONJUGATED HEPCIDIN MIMETICS |
| MX2022008740A (es) | 2020-01-15 | 2022-09-23 | Janssen Biotech Inc | Peptidos inhibidores del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias. |
| IL302996A (en) | 2020-11-20 | 2023-07-01 | Janssen Pharmaceutica Nv | Compositions of peptide inhibitors of the interleukin-23 receptor |
| WO2024015958A1 (en) * | 2022-07-14 | 2024-01-18 | Janssen Pharmaceutica Nv | Cyclic peptide inhibitors of il-23 |
| WO2024155546A1 (en) * | 2023-01-16 | 2024-07-25 | Janssen Pharmaceutica Nv | Peptide inhibitors of interleukin-23 receptor |
| WO2024155553A1 (en) | 2023-01-16 | 2024-07-25 | Janssen Pharmaceutica Nv | Lipidated peptide inhibitors of interleukin-23 receptor |
| WO2024155551A1 (en) * | 2023-01-16 | 2024-07-25 | Janssen Pharmaceutica Nv | Polycyclic peptide inhibitors of interleukin-23 receptor |
| WO2024163643A1 (en) * | 2023-01-31 | 2024-08-08 | Janssen Pharmaceutica Nv | Methods for preparing crystalline peptide inhibitors of interleukin-23 receptor |
| WO2024186613A1 (en) * | 2023-03-03 | 2024-09-12 | Janssen Pharmaceutica Nv | Interleukin-23 receptor antagonist peptides for use in the treatment of psoriasis |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10787490B2 (en) * | 2015-07-15 | 2020-09-29 | Protaganist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| US20230312700A1 (en) * | 2018-06-20 | 2023-10-05 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a tnf inhibitor |
| US11845808B2 (en) * | 2020-01-15 | 2023-12-19 | Janssen Biotech, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
-
2022
- 2022-07-14 IL IL310061A patent/IL310061A/en unknown
- 2022-07-14 TW TW111126551A patent/TW202330013A/zh unknown
- 2022-07-14 CA CA3226532A patent/CA3226532A1/en active Pending
- 2022-07-14 KR KR1020247004803A patent/KR20240034224A/ko unknown
- 2022-07-14 AU AU2022311814A patent/AU2022311814A1/en active Pending
- 2022-07-14 EP EP22842897.5A patent/EP4370146A2/en active Pending
- 2022-07-14 MX MX2024000760A patent/MX2024000760A/es unknown
- 2022-07-14 WO PCT/US2022/037205 patent/WO2023288019A2/en active Application Filing
- 2022-07-14 PE PE2024000076A patent/PE20240595A1/es unknown
- 2022-07-14 JP JP2024501765A patent/JP2024525732A/ja active Pending
- 2022-07-14 CN CN202280061964.XA patent/CN118055773A/zh active Pending
-
2023
- 2023-10-26 US US18/495,457 patent/US20240173309A1/en active Pending
-
2024
- 2024-01-12 DO DO2024000011A patent/DOP2024000011A/es unknown
- 2024-01-30 CO CONC2024/0000999A patent/CO2024000999A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022311814A1 (en) | 2024-02-29 |
| TW202330013A (zh) | 2023-08-01 |
| PE20240595A1 (es) | 2024-03-21 |
| EP4370146A2 (en) | 2024-05-22 |
| US20240173309A1 (en) | 2024-05-30 |
| MX2024000760A (es) | 2024-04-18 |
| WO2023288019A2 (en) | 2023-01-19 |
| WO2023288019A3 (en) | 2023-03-02 |
| JP2024525732A (ja) | 2024-07-12 |
| CA3226532A1 (en) | 2023-01-19 |
| DOP2024000011A (es) | 2024-07-31 |
| CN118055773A (zh) | 2024-05-17 |
| IL310061A (en) | 2024-03-01 |
| KR20240034224A (ko) | 2024-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2024000999A2 (es) | Inhibidores peptídicos lipídicos del receptor de interleucina-23 | |
| UY39527A (es) | Composiciones de los inhibidores de peptidos del receptor de interleucina-23 | |
| DOP2022000147A (es) | Inhibidores de péptidos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias | |
| AR126457A1 (es) | Inhibidores peptídicos bicíclicos del receptor de interleuquina-23 | |
| AR119389A1 (es) | Inhibidores de péptidos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias | |
| MX2022008740A (es) | Peptidos inhibidores del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias. | |
| CL2021000343A1 (es) | Inhibidores peptídicos del receptor de interleucina 23 (divisional de la solicitud n° 201800128) | |
| BR112022000328A2 (pt) | Inibidores peptídicos do receptor de interleucina-23 e seu uso para tratar doenças inflamatórias | |
| ECSP16071151A (es) | Inhibidores de dihidropirrolopiridina de ror-gamma | |
| CO2019001212A2 (es) | Composiciones y métodos de inhibición del masp-3 para el tratamiento de diversas enfermedades y trastornos | |
| CO2020005351A2 (es) | Uso de inhibidores de p38 para reducir la expresión de dux4 | |
| CL2023002223A1 (es) | Inhibidores de cdk2 y métodos de uso de los mismos | |
| CL2022000201A1 (es) | Inhibidores tricíclicos de kars dependientes de akr1c3 | |
| CO2022010547A2 (es) | Compuestos y usos de los mismos | |
| CO2023013150A2 (es) | Inhibidores de mk2 y usos de estos | |
| DOP2023000223A (es) | Composiciones y métodos para inhibir cetohexoquinasa (khk) | |
| CO2021001174A2 (es) | Inhibidores de ckd8/19 | |
| UY38133A (es) | Nuevos inhibidores de cdk8/19 | |
| CL2020002398A1 (es) | Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida ("tcd") | |
| CO2024009144A2 (es) | Inhibidores de cinasa met |